XFZYD impedes tumour invasion, presumably by inhibiting JNK signalling, and stimulating caspase-mediated apoptosis, thus, highlighting specific key drug targets and crucial strategies for cancer clinical treatment. This evidence concerns the gene MAPK8 and neoplasm.